Differences in p53 target gene expression with and without nutlin-3 were evaluated in patient-derived B-CLL cells, showing that all wild-type p53 samples accumulated p53 after nutlin-3 treatment but only 13 out of 16 samples induced the same set of genes [161]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.